Skip to main content

Table 6 Percentages of patients meeting different levels of IBS-QOL total score improvement

From: Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients

Improvement from baseline to Week 12 Placebo Eluxadoline 100 mg Difference between treatment groups
0 80.3% 90.6% 10.30%
5 70.4% 80.5% 10.11%
10 57.9% 74.2% 16.32%
15 46.1% 62.9% 16.84%
20 32.2% 52.8% 20.59%
25 21.7% 41.5% 19.80%
30 19.1% 30.8% 11.74%